Fox Chase Cancer Center News

PHILADELPHIA (January 28, 2020) – The OCRA Liz Tilberis Early Career Award provides James Duncan, PhD, and seven other 2020 award winners with a three-year grant of $150,000 per year to support their research on ovarian cancer.

PHILADELPHIA (January 27, 2020) – Edna Cukierman, PhD, received a $292,999 grant from Worldwide Cancer Research for a two-year study of the microenvironment of pancreatic cancer cells.

PHILADELPHIA (January 23, 2020) – The three-year certification for oncology practices that meet nationally recognized standards for quality and safety in cancer care is recognized by the QOPI program, a wholly owned subsidiary of the American Society of Clinical Oncology (ASCO), builds on ASCO’s Quality Oncology Practice Initiative (QOPI).

PHILADELPHIA (January 23, 2020) –  The mission of the ASMB is to promote basic, translational, and clinical research on the extracellular matrix, the noncellular portion of tissue that provides structural and biochemical support to surrounding cells.

PHILADELPHIA (January 22, 2020) – In the first published study since the market release of robot-assisted bronchoscopy, researchers at Fox Chase Cancer Center have found the technology to be safe, feasible, and reliable for achieving diagnoses for lung cancer.

PHILADELPHIA (January 20, 2020) – Claudia J. Kasales, MD, MHA, FACR, who will be joining the Department of Diagnostic Imaging as a professor on the academic clinician track. She will begin work at Fox Chase on February 1, 2020.

PHILADELPHIA (January 16, 2020)—An eight-year multicenter trial to study how often and how fast pancreatic cysts progress to cancer is launching today. Fox Chase Cancer Center serves as the headquarters for the project, although the trial is open to participation at hundreds of sites around the country.

PHILADELPHIA (January 14, 2020) – Johnathan R. Whetstine, PhD, a program leader for the Cancer Epigenetics Program at Fox Chase Cancer Center, was awarded the American Lung Association’s Lung Cancer Discovery Award, a $100,000 grant to research epigenetic factors affecting lung cancer.